CY1124281T1 - Θεραπευτικη χρηση ειδικου προσδετη σε σχετικες me msrv ασθενειες - Google Patents

Θεραπευτικη χρηση ειδικου προσδετη σε σχετικες me msrv ασθενειες

Info

Publication number
CY1124281T1
CY1124281T1 CY20211100481T CY211100481T CY1124281T1 CY 1124281 T1 CY1124281 T1 CY 1124281T1 CY 20211100481 T CY20211100481 T CY 20211100481T CY 211100481 T CY211100481 T CY 211100481T CY 1124281 T1 CY1124281 T1 CY 1124281T1
Authority
CY
Cyprus
Prior art keywords
msrv
related diseases
seq
therapeutic use
specific adapter
Prior art date
Application number
CY20211100481T
Other languages
English (en)
Inventor
Corinne Bernard
Alois Bernhardt Lang
Hervé Perron
Jean-Baptiste Bertrand
Original Assignee
Geneuro Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneuro Sa filed Critical Geneuro Sa
Publication of CY1124281T1 publication Critical patent/CY1124281T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση ασχολείται με έναν προσδέτη που περιλαμβάνει εκάστη από τις προσδιοριστικές περιοχές συμπληρωματικότητας (CDRs) που εκτίθενται στις SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 και SEQ ID No. 6 για χρήση σε μία μέθοδο θεραπείας.
CY20211100481T 2008-07-08 2021-06-02 Θεραπευτικη χρηση ειδικου προσδετη σε σχετικες me msrv ασθενειες CY1124281T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12961308P 2008-07-08 2008-07-08
US20258109P 2009-03-13 2009-03-13
US21318909P 2009-05-15 2009-05-15
PCT/EP2009/058663 WO2010003977A1 (en) 2008-07-08 2009-07-08 Therapeutic use of specific ligand in msrv associated diseases
EP09780311.8A EP2315777B1 (en) 2008-07-08 2009-07-08 Therapeutic use of specific ligand in msrv associated diseases

Publications (1)

Publication Number Publication Date
CY1124281T1 true CY1124281T1 (el) 2022-07-22

Family

ID=41165692

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100776T CY1119185T1 (el) 2008-07-08 2017-07-20 Θεραπευτικη χρηση ειδικου προσδετη σε σχετικες me msrv ασθενειες
CY20211100481T CY1124281T1 (el) 2008-07-08 2021-06-02 Θεραπευτικη χρηση ειδικου προσδετη σε σχετικες me msrv ασθενειες

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171100776T CY1119185T1 (el) 2008-07-08 2017-07-20 Θεραπευτικη χρηση ειδικου προσδετη σε σχετικες me msrv ασθενειες

Country Status (24)

Country Link
US (4) US8715656B2 (el)
EP (2) EP3211005B1 (el)
JP (3) JP6058264B2 (el)
KR (1) KR101682040B1 (el)
CN (1) CN102143975B (el)
AU (1) AU2009268025B2 (el)
BR (1) BRPI0915667B8 (el)
CA (1) CA2729869C (el)
CY (2) CY1119185T1 (el)
DK (1) DK3211005T3 (el)
EA (1) EA024655B1 (el)
ES (2) ES2633965T3 (el)
HK (2) HK1158232A1 (el)
HR (2) HRP20171067T1 (el)
HU (2) HUE054712T2 (el)
IL (1) IL210204A (el)
LT (2) LT2315777T (el)
MX (1) MX2010014319A (el)
NZ (1) NZ590515A (el)
PL (2) PL2315777T3 (el)
PT (2) PT3211005T (el)
SI (2) SI3211005T1 (el)
WO (1) WO2010003977A1 (el)
ZA (1) ZA201100446B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5087625B2 (ja) 2006-09-01 2012-12-05 セラピューティック・ヒューマン・ポリクローナルズ・インコーポレーテッド 非ヒトトランスジェニック動物におけるヒトまたはヒト化免疫グロブリンの発現強化
MX2010014319A (es) * 2008-07-08 2011-05-19 Geneuro Sa Uso terapeutico de ligando especifico en enfermedades asociadas con msrv.
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
UA119032C2 (uk) 2012-10-02 2019-04-25 Женеро Са Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w
EP2949342A1 (en) * 2014-05-28 2015-12-02 Geneuro SA Antiretroviral drug targeting human endogenous retrovirus
SG10202006332PA (en) * 2015-10-29 2020-08-28 Hoffmann La Roche Transgenic rabbit with common light chain
JP2018028538A (ja) * 2016-08-12 2018-02-22 公立大学法人名古屋市立大学 統合失調症とその関連疾患の診断用マーカー及びその使用
WO2019201908A1 (en) 2018-04-17 2019-10-24 Geneuro Sa Method for the detection of the soluble hydrophilic oligomeric form of herv-w envelope protein
EP3916015A1 (en) * 2020-05-28 2021-12-01 Geneuro SA Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases
CN113940993B (zh) * 2021-12-20 2022-02-22 深圳万可森生物科技有限公司 一种鲈鱼弹状病毒g2-2m亚单位疫苗及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
EP0814166A3 (en) 1989-08-09 1998-05-13 DeKalb Genetics Corporation Methods and compositions for the production of stably transformed fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7473423B2 (en) * 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
FR2734842B1 (fr) 1995-06-02 1998-02-27 Rhone Poulenc Agrochimie Sequence adn d'un gene de l'hydroxy-phenyl pyruvate dioxygenase et obtention de plantes contenant un gene de l'hydroxy-phenyl pyruvate dioxygenase, tolerantes a certains herbicides
FR2736926B1 (fr) 1995-07-19 1997-08-22 Rhone Poulenc Agrochimie 5-enol pyruvylshikimate-3-phosphate synthase mutee, gene codant pour cette proteine et plantes transformees contenant ce gene
EP1224291A1 (en) * 1999-10-28 2002-07-24 Universite De Geneve Multiple sclerosis-related superantigen
CA2522894C (en) * 2003-05-31 2013-06-25 Micromet Ag Pharmaceutical composition comprising a bispecific antibody specific for epcam
FR2865403B1 (fr) 2004-01-23 2009-06-12 Biomerieux Sa Composition pour le traitement d'une pathologie associee a la msrv/herv-w
UA94019C2 (ru) 2004-07-09 2011-04-11 Чугаи Сейяку Кабусики Кайся Антитело, которое специфически связывается с глипиканом 3 (gpc3)
KR100918746B1 (ko) 2004-09-06 2009-09-24 교와 핫꼬 기린 가부시키가이샤 항 ａ３３ 항체
EP1829961A4 (en) * 2004-12-22 2008-06-04 Chugai Pharmaceutical Co Ltd PROCESS FOR PREPARING ANTIBODY USING A CELL WHOSE FUCOSE CARRIER FUNCTION IS INHIBITED
WO2006138627A2 (en) 2005-06-16 2006-12-28 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
EP1921137A4 (en) 2005-06-21 2011-01-26 Med & Biological Lab Co Ltd ANTIBODIES WITH INHIBITOR EFFECT ON THE FORMATION OF AMYLOID FIBRILLES
FR2912314B1 (fr) * 2007-02-09 2012-08-03 Geneuro Sa Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w.
MX2010014319A (es) * 2008-07-08 2011-05-19 Geneuro Sa Uso terapeutico de ligando especifico en enfermedades asociadas con msrv.

Also Published As

Publication number Publication date
LT3211005T (lt) 2021-08-25
ES2633965T3 (es) 2017-09-26
ES2875762T3 (es) 2021-11-11
BRPI0915667A2 (pt) 2017-01-17
US20110243962A1 (en) 2011-10-06
IL210204A0 (en) 2011-03-31
HK1243436A1 (zh) 2018-07-13
IL210204A (en) 2015-03-31
JP6058264B2 (ja) 2017-01-11
EP3211005B1 (en) 2021-03-17
US10059758B2 (en) 2018-08-28
HRP20171067T1 (hr) 2017-10-06
HUE054712T2 (hu) 2021-09-28
PT3211005T (pt) 2021-06-15
DK3211005T3 (da) 2021-06-07
NZ590515A (en) 2013-01-25
US9550824B2 (en) 2017-01-24
PL2315777T3 (pl) 2017-10-31
HRP20210892T1 (hr) 2021-11-26
SI2315777T1 (sl) 2017-09-29
CY1119185T1 (el) 2018-02-14
ZA201100446B (en) 2012-01-25
AU2009268025B2 (en) 2014-07-31
CN102143975A (zh) 2011-08-03
EA024655B1 (ru) 2016-10-31
US20140220026A1 (en) 2014-08-07
JP2011527887A (ja) 2011-11-10
JP6109869B2 (ja) 2017-04-05
HUE033803T2 (en) 2018-01-29
WO2010003977A1 (en) 2010-01-14
CA2729869A1 (en) 2010-01-14
MX2010014319A (es) 2011-05-19
CN102143975B (zh) 2014-12-31
US20180057569A1 (en) 2018-03-01
BRPI0915667B1 (pt) 2020-10-13
EA201100160A1 (ru) 2011-08-30
JP2017158550A (ja) 2017-09-14
PT2315777T (pt) 2017-07-25
PL3211005T3 (pl) 2021-11-29
LT2315777T (lt) 2017-10-25
JP2015157812A (ja) 2015-09-03
AU2009268025A1 (en) 2010-01-14
US8715656B2 (en) 2014-05-06
EP3211005A1 (en) 2017-08-30
EP2315777A1 (en) 2011-05-04
KR20110031969A (ko) 2011-03-29
SI3211005T1 (sl) 2021-06-30
KR101682040B1 (ko) 2016-12-02
US20170107274A1 (en) 2017-04-20
HK1158232A1 (en) 2012-07-13
BRPI0915667B8 (pt) 2021-05-25
CA2729869C (en) 2018-02-13
US9815888B2 (en) 2017-11-14
JP6495361B2 (ja) 2019-04-03
EP2315777B1 (en) 2017-04-26

Similar Documents

Publication Publication Date Title
CY1124281T1 (el) Θεραπευτικη χρηση ειδικου προσδετη σε σχετικες me msrv ασθενειες
CY1123051T1 (el) Ταπενταδολη για προληψη και θεραπεια καταθλιψης και αγχους
CY1122428T1 (el) Θεραπευτικη αγωγη της παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας με διειδικα αντισωματα εναντι cd3xcd19
CY1123052T1 (el) Συνθεσεις και μεθοδοι σχετικες με παραλλαγες της πρωτεϊνες α (spa)
CY1122366T1 (el) Θεραπεια της οξειας λεμφοβλαστικης λευχαιμιας
CY1118349T1 (el) Παραγοντες συνδεσης me cd19 και χρησεις αυτων
CY1121065T1 (el) Αναστολεις ιβατ για την αγωγη ηπατικων νοσων
CY1124103T1 (el) Δοσολογικο σχημα που σχετιζεται με ενεσιμους εστερες παλιπεριδονης μακρας δρασης
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1118845T1 (el) Πρωτεϊνες συνδεσης αντιγονου υποδοχεα α il-17
CY1119213T1 (el) Πρωτεϊνη p75ntr συνδεσης νευροτροφινης για θεραπευτικη χρηση
CY1118530T1 (el) Glyx-13 για χρηση σε μεθοδο θεραπευτικης αγωγης ανθεκτικης σε θεραπεια καταθλιψης
EA201490994A1 (ru) Функционально-модифицированные олигонуклеотиды и их субъединицы
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1125948T1 (el) Σχημα αγωγης που χρησιμοποιει νερατινιμπη για τον καρκινο του μαστου
CY1112288T1 (el) Θεραπεια του καρκινου με αντισωματα κατα της il-1a
CY1115254T1 (el) Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις
EA201500156A3 (ru) Доставка антител посредством модульного домена распознавания
CY1116494T1 (el) Θεραπευτικη αγωγη θρομβοεμβολικων διαταραχων με ριβαροξαβανη
MX2010005244A (es) Composiciones y métodos para la terapia y el diagnóstico de influenza.
CY1115975T1 (el) Ταπενταδολη για τη θεραπεια πονου σε αρθριτιδα
CY1119800T1 (el) Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper